Results 131 to 140 of about 1,247,370 (242)

When molecular biology transforms clinical oncology: the EGFR journey in colorectal cancer. [PDF]

Mol Oncol
Vitiello PP, Saoudi González N, Bardelli A.   +2 more
europepmc   +1 more source

Training in Radiation and Clinical Oncology in Europe. [PDF]

J Med Educ Curric Dev, 2023
Lara PC, Benstead K, Erikssen JG.
europepmc   +1 more source

Early metastasis is characterized by Gr1+ cell dysregulation and is inhibited by immunomodulatory nanoparticles

Molecular Oncology, EarlyView.
Breast cancer metastasis is associated with myeloid cell dysregulation and the lung‐specific accumulation of tumor‐supportive Gr1+ cells. Gr1+ cells support metastasis, in part, through a CHI3L1‐mediated mechanism, which can be targeted and inhibited with cargo‐free, polymeric nanoparticles.
Jeffrey A. Ma, Sophia M. Orbach, Kate V. Griffin, Kathryn Kang, Yining Zhang, Rebecca S. Pereles, Ian A. Schrack, Guillermo Escalona, Jacqueline S. Jeruss, Lonnie D. Shea   +9 more
wiley   +1 more source

Harnessing exosomes as cancer biomarkers in clinical oncology. [PDF]

Cancer Cell Int
Ghosh S, Rajendran RL, Mahajan AA, Chowdhury A, Bera A, Guha S, Chakraborty K, Chowdhury R, Paul A, Jha S, Dey A, Dubey A, Gorai S, Das P, Hong CM, Krishnan A, Gangadaran P, Ahn BC.   +17 more
europepmc   +1 more source

2023 American Society of Clinical Oncology (ASCO) Symposium: Meeting highlights. [PDF]

Can Urol Assoc J, 2023
Basappa NS, Emmenegger U, Sridhar SS, Wood L, Black PC.   +4 more
europepmc   +1 more source

Detecting homologous recombination deficiency for breast cancer through integrative analysis of genomic data

Molecular Oncology, EarlyView.
This study develops a semi‐supervised classifier integrating multi‐genomic data (1404 training/5893 validation samples) to improve homologous recombination deficiency (HRD) detection in breast cancer. Our method demonstrates prognostic value and predicts chemotherapy/PARP inhibitor sensitivity in HRD+ tumours.
Rong Zhu, Katherine Eason, Suet‐Feung Chin, Paul A. W. Edwards, Raquel Manzano Garcia, Richard Moulange, Jia Wern Pan, Soo Hwang Teo, Sach Mukherjee, Maurizio Callari, Carlos Caldas, Stephen‐John Sammut, Oscar M. Rueda   +12 more
wiley   +1 more source

Comparative Evaluation of LLMs in Clinical Oncology. [PDF]

NEJM AI
Rydzewski NR, Dinakaran D, Zhao SG, Ruppin E, Turkbey B, Citrin DE, Patel KR.   +6 more
europepmc   +1 more source

Evaluation of KRAS and NRAS mutations in metastatic colorectal cancer: an 8‐year study of 10 754 patients in Turkey

Molecular Oncology, EarlyView.
This nationwide study evaluated KRAS and NRAS mutations in 10 754 Turkish patients with metastatic colorectal cancer. The results revealed a mutation frequency of 51.1%, with 46.6% having KRAS mutations, 4.5% having NRAS mutations, and 48.5% being wild‐type for both.
Gozde Kavgaci, Izzet Akiva, Yavuz Hakan Ozon, Hakan Berkil, Huseyin Karadayi, Omer Dizdar, Suayib Yalcin   +6 more
wiley   +1 more source

Clinical presentation and treatment outcomes of gastric adenocarcinoma patients: a retrospective study from Ain Shams Clinical Oncology Department. [PDF]

Ecancermedicalscience
Alorabi MO, El-Bassiouny M, El Khodary DAEG, El Din MMAE, Elsayed AMMA, Reda C.   +5 more
europepmc   +1 more source

A Quantitative Multiparametric MRI Analysis Platform for Estimation of Robust Imaging Biomarkers in Clinical Oncology. [PDF]

Tomography, 2023
LoCastro E, Paudyal R, Konar AS, LaViolette PS, Akin O, Hatzoglou V, Goh AC, Bochner BH, Rosenberg J, Wong RJ, Lee NY, Schwartz LH, Shukla-Dave A.   +12 more
europepmc   +1 more source